Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.
DNA damage response
[177Lu]Lu-PSMA
[225Ac]Ac-PSMA
prostate cancer
proteomics/phosphoproteomics
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
02
09
2020
revised:
11
11
2020
pubmed:
6
12
2020
medline:
6
1
2022
entrez:
5
12
2020
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is effective against prostate cancer (PCa), but all patients relapse eventually. Poor understanding of the underlying resistance mechanisms represents a key barrier to development of more effective RLT. We investigate the proteome and phosphoproteome in a mouse model of PCa to identify signaling adaptations triggered by PSMA RLT.
Identifiants
pubmed: 33277393
pii: jnumed.120.256263
doi: 10.2967/jnumed.120.256263
pmc: PMC8882874
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
989-995Subventions
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092131
Pays : United States
Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Clin Cancer Res. 2008 Jun 1;14(11):3555-61
pubmed: 18519789
J Nucl Med. 2021 Feb;62(2):228-231
pubmed: 32646877
J Biol Chem. 2019 May 31;294(22):8699-8710
pubmed: 30992362
Sci Rep. 2020 Jun 23;10(1):10196
pubmed: 32576907
J Nucl Med. 2017 Nov;58(11):1786-1792
pubmed: 28546332
Cell Chem Biol. 2020 Feb 20;27(2):197-205.e6
pubmed: 31734178
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1454-8
pubmed: 11171972
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
J Biol Chem. 2002 Aug 9;277(32):29304-14
pubmed: 12015328
Annu Rev Biochem. 1988;57:349-74
pubmed: 3052277
J Clin Invest. 2018 Aug 31;128(9):3926-3940
pubmed: 29952768
Eur Urol. 2017 May;71(5):740-747
pubmed: 27989354
Int J Oncol. 2019 Dec;55(6):1287-1295
pubmed: 31638190
Genes (Basel). 2017 Feb 16;8(2):
pubmed: 28212321
Mol Cell Oncol. 2018 Sep 25;5(6):e1511207
pubmed: 30525089
Int J Mol Sci. 2016 Jan 14;17(1):
pubmed: 26784176
Clin Cancer Res. 2020 Jun 15;26(12):2946-2955
pubmed: 31932492
Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1507-12
pubmed: 11121656
BMC Genomics. 2009 Sep 07;10:417
pubmed: 19735555
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):355-361
pubmed: 27986349
Prostate. 2012 Sep 15;72(13):1423-30
pubmed: 22290244
Cancer Discov. 2013 Nov;3(11):1245-53
pubmed: 24027196
Semin Oncol. 2003 Oct;30(5):709-16
pubmed: 14571418
J Nucl Med. 2013 May;54(5):762-9
pubmed: 23492884
Cell Death Dis. 2014 Oct 02;5:e1437
pubmed: 25275598
Cancer Cell. 2007 Feb;11(2):175-89
pubmed: 17292828
Pharmaceuticals (Basel). 2019 Oct 15;12(4):
pubmed: 31618864
J Nucl Med. 2018 May;59(5):795-802
pubmed: 29326358
Nucleic Acids Res. 2010 Jul;38(12):3975-83
pubmed: 20215435
Int J Mol Sci. 2020 Jun 25;21(12):
pubmed: 32630372
J Biol Chem. 2015 Jul 3;290(27):17029-40
pubmed: 25995454
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
Cancer Discov. 2015 Jun;5(6):636-51
pubmed: 25829425
J Nucl Med. 2020 May;61(5):683-688
pubmed: 31601699
Cell. 2014 Oct 9;159(2):440-55
pubmed: 25263330
Eur J Cancer. 2020 Sep;136:16-24
pubmed: 32634759
Cancer Res. 2016 Jan 15;76(2):283-92
pubmed: 26554830
J Nucl Med. 2019 Sep;60(9):1293-1300
pubmed: 30850485
Oncotarget. 2016 Jan 12;7(2):1341-53
pubmed: 26625310
Radiother Oncol. 2018 Aug;128(2):283-300
pubmed: 29929859
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138
Mol Cancer Ther. 2020 Jan;19(1):26-38
pubmed: 31582533
Endocr Relat Cancer. 2011 Mar 09;18(2):245-55
pubmed: 21317204